BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova to Participate at the 38th Annual ROTH Conference

MediciNova (MNOV)MediciNovaConference / presentation

LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO,

Open original release

Related news

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

ABOSAcumen Pharmaceuticals2026-05-07 20:00 EST

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MNOVMediciNova2026-05-26 23:00 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

HRMYHarmony Biosciences2026-03-31 12:05 EST

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

MNOVMediciNova2026-04-27 23:00 EST

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

ANNXAnnexon, Inc.2026-04-08 20:05 EST

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-05-26 23:00 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-04-27 23:00 EST

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MNOVMediciNova2026-03-16 11:00 EST

MediciNova to Participate at the 38th Annual ROTH Conference

MNOVMediciNova2026-01-29 23:00 EST

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-01-06 14:00 EST

2026 New Year’s Greetings from the CEO

Stock data

Close
1.32 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States